Pharmacosmos' revenue grows by USD 16m despite corona challenges
Investments in the US and China have affected Pharmacosmos' bottom line, but the company has increased its revenue and expects growth to continue in the new financial year.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
In a previous accounting report, Pharmacosmos warned that it would probably end the year with a deficit on the bottom line, its first in 15 years -- and this prediction came true.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos launches cell therapy market offensive
For subscribers
.jpg&w=384&q=75)
